Despite the range of disease-modifying treatments for multiple sclerosis (MS), only a few of these are currently available for the progressive form (PMS). Insidiously, patients with PMS lose physical, communicative and cognitive capacity, and may live with palliative care needs and facing a possible further deterioration and death, for a long time. Life expectancy among patients with MS is reduced by 7-14 years, and the risk of suicide is 2-7.5 times higher than that of the general population. 1 In this trajectory, it can be difficult to form an accurate prognosis of 'when' the next step towards loss of functional capacity or death will happen. As deterioration in functioning continues and acute events repeat, the indication for invasive procedures such as percutaneous endoscopic gastrostomy (PEG), mechanical ventilation or tracheostomy arises. These procedures may extend survival, but change dramatically the way of life of the patients and their caregivers, with a need for readjustment to a more or less sophisticated technologically supported life including the management of new and different symptoms. Along with safety and effectiveness, complex ethical issues (including autonomy and dignity-conserving care) underlie offering, withholding or withdrawing such treatments.
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Respect of patient preferences and values
Many patients with PMS express a wish for truthful and competent communication about end-of-life issues, advance care planning (ACP), and the wish to hasten death. [2] [3] [4] Besides death-related concerns, patients and their caregivers have a large range of unmet needs which transcend purely medical issues to embrace psychosocial aspects. 3, 4 However, their satisfaction with the degree of communication on these topics is rather poor. 3, 4 Difficulty in articulating and deliberating on needs is an additional challenge, which should be identified and addressed early in the disease trajectory. ACP is strongly recommended, especially when progression towards severe cognitive compromise is present. ACP is a process by which the patient and the caring physician through shared decision-making establish (and re-establish) future goals of care, or may appoint a substitute decision-maker. It is considered most effective when started in a timely fashion, allowing patients, their loved ones and the health professionals to proactively address the challenges together, while the patient has the ability to express these views, and avoid unplanned care for crisis intervention. ACP can lead to an advance directive which includes end-of-life decisions such as do-notresuscitate, no assisted nutrition/hydration, the anticipation of crises and the provision of medication to cope with these and the possibility of palliative sedation. Who should manage all the above-mentioned issues? Which is the best care model for patients with PMS who live with or are shifting towards an irreversible severe disability? A comprehensive care model A full integration of neurology, rehabilitation and palliative services through an interdisciplinary and multi-professional team has been proposed for MS and other neurodegenerative conditions. 5 As from this model, the neurological and rehabilitation competences should be merged with the core competences of palliative medicine (which, if not integrated, is inadequate to respond to the needs of patients with MS). The use of 'triggers', based on the clinical changes and the views of the patient and family, to suggest referral to specialist palliative care have been recommended. 6 Rather than merely providing endof-life care, this approach aims to improve the palliative care skills and competencies of health professionals caring for the patients from the early stage of PMS, including those who are actively undergoing disease-targeted therapies. An 'early and simultaneous' palliative approach (as stated in the World Health Organization (WHO) definition of palliative care) can produce more efficient care 
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A Solari and E Pucci associated with cost savings. In this regard, it is unfortunate that palliative health professionals are not mentioned in the fine grained list of professionals and disciplines involved at the various levels of the MS patient care. 7 To obtain this integration, action is needed at three levels. First, at a cultural level, initiatives to increase public awareness about palliative care and ACP within the general population. Second, at an educational level, programmes in communication and shared decision-making for MS clinicians (in particular physicians and nurses) to improve their competences, self-confidence and their experiences of care. Cross-training in neurology, palliative medicine, and rehabilitation should also be part of the undergraduate, postgraduate and continuous medical education curricula. Third, at a clinical research level, there is need to increase the evidence base for integrated health care models. As for the latter, to date, two randomised controlled trials on a homebased specialist palliative service produced encouraging findings on some symptoms, 8, 9 quality of life 9 and caregiver burden. 8 A home-based palliative approach intervention also reduced symptoms burden. 10 A large clinical trial on a mixed population has been recently concluded, and updated guideline document 4,6 will be published soon. Further research is needed, including, for example, interventions for the needs of caregivers and timing of ACP.
In conclusion, an early and simultaneous palliative approach should be a care model for persons with PMS, and the multidisciplinary MS Care Unit should be fully integrated with palliative care competencies. Specialist palliative care should be offered when needed. This is in order to provide an efficient holistic and person-centred system of care along the entire MS trajectory.
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